TEGO SCIENCE

Pipeline

Home>R&D>Pipeline

Growth drivers of Tego Science leading the bio industry

Pipeline * Hover your mouse over the gray area

  • Skin

    Holoderm® Information
    Product
    name    		 Holoderm®
    Indication Burn
    Active
    Ingredient    		 Autologous Keratinocytes
    Development
    Status    		 Approved in 2002
    Kaloderm® Information
    Product
    name    		 Kaloderm®
    Indication Burn
    Active
    Ingredient    		 Allogeneic Keratinocytes
    Development
    Status    		 Approved in 2005
    TPX-108 Information
    Product
    name    		 TPX-108
    Indication Cutaneous wounds
    Active
    Ingredient    		 Chemokine
    Development
    Status    		 Pre-clinical phase

  • Eyes

    TPX-107 Information
    Product
    name    		 TPX-107
    Indication Corneal defects
    Active
    Ingredient    		 Autologous Cultured Cornea
    Development
    Status    		 Investigator’s trial

  • Tear trough wrinkles

    Rosmir® Information
    Product
    name    		 Rosmir®
    Indication Augmentation of nasojugal groove
    Active
    Ingredient    		 Autologous Fibroblasts
    Development
    Status    		 Approved in 2017
    TPX-121 Information
    Product
    name    		 TPX-121
    Indication Wrinkle
    Active
    Ingredient    		 Allogeneic dermal fibroblasts
    Development
    Status    		 Non-clinical study

  • Oral

    TPX-112/TPX-113 Information
    Product
    name    		 TPX-112/TPX-113
    Indication Oral mucosal defects
    Active
    Ingredient    		 Autologous Cultured Mucosal
    Allogeneic Cultured Mucosal
    Development
    Status    		 Pre-clinical phase

  • Shoulder

    TPX-114/115 Information
    Product
    name    		 TPX-114/115
    Indication Rotator-cuff tear
    Active
    Ingredient    		 Autologous Fibroblasts
    Allogeneic Fibroblasts
    Development
    Status    		 Clinical I/III phase
    Pre-clinical phase

  • Knee

    TPX-109 Information
    Product
    name    		 TPX-109
    Indication Cartilage defects
    Active
    Ingredient    		 Chemokine
    Development
    Status    		 Pre-clinical phase

  • Foot

    Kaloderm® Information
    Product
    name    		 Kaloderm®
    Indication Diabetic Foot Ulcer(DFU)
    Active
    Ingredient    		 Allogeneic Keratinocytes
    Development
    Status    		 Approved in 2010